These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 21068649

  • 1. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
    Ramasamy K, Narayan SK, Shewade DG, Chandrasekaran A.
    Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
    [Abstract] [Full Text] [Related]

  • 2. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y, Yang JF, Qi XL, Wang YQ, Wang WZ, Chen B.
    Zhonghua Yi Xue Za Zhi; 2004 Oct 17; 84(20):1686-9. PubMed ID: 15569425
    [Abstract] [Full Text] [Related]

  • 3. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J, Steijns LS, van Weelden MJ, de Haan K.
    Pharmacogenetics; 2001 Jun 17; 11(4):287-91. PubMed ID: 11434505
    [Abstract] [Full Text] [Related]

  • 4. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
    Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH.
    Ther Drug Monit; 2004 Oct 17; 26(5):534-40. PubMed ID: 15385837
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.
    Ebid AH, Ahmed MM, Mohammed SA.
    Ther Drug Monit; 2007 Jun 17; 29(3):305-12. PubMed ID: 17529887
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy.
    Twardowschy CA, Werneck LC, Scola RH, Borgio JG, De Paola L, Silvado C.
    Seizure; 2013 Apr 17; 22(3):194-7. PubMed ID: 23298603
    [Abstract] [Full Text] [Related]

  • 11. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
    Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB.
    Proc Natl Acad Sci U S A; 2005 Apr 12; 102(15):5507-12. PubMed ID: 15805193
    [Abstract] [Full Text] [Related]

  • 12. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ, Yen MF, Hu OY, Lin MS, Hsiong CH, Hung CC, Liou HH.
    Pharmacotherapy; 2008 Jan 12; 28(1):35-41. PubMed ID: 18154472
    [Abstract] [Full Text] [Related]

  • 13. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H.
    Clin Pharmacol Ther; 2004 Mar 12; 75(3):204-12. PubMed ID: 15001972
    [Abstract] [Full Text] [Related]

  • 14. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
    Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE.
    Arq Neuropsiquiatr; 2011 Apr 12; 69(2A):153-8. PubMed ID: 21537551
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.
    Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K.
    Clin Pharmacol Ther; 2001 Aug 12; 70(2):175-82. PubMed ID: 11503012
    [Abstract] [Full Text] [Related]

  • 17. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM.
    Clin Pharmacol Ther; 2004 Mar 12; 75(3):198-203. PubMed ID: 15001971
    [Abstract] [Full Text] [Related]

  • 18. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
    Lee SY, Lee ST, Kim JW.
    J Biochem Mol Biol; 2007 May 31; 40(3):448-52. PubMed ID: 17562299
    [Abstract] [Full Text] [Related]

  • 19. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
    Yildirim H, Tamer L, Sucu N, Atik U.
    Med Princ Pract; 2008 May 31; 17(6):464-7. PubMed ID: 18836275
    [Abstract] [Full Text] [Related]

  • 20. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L, Márki-Zay J, Fodor L, Kondacs A, Paragh G, Katona A.
    Orv Hetil; 2005 Apr 17; 146(16):739-43. PubMed ID: 15889670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.